Alan Resnick, MD
Allergy · Orland Park, ILNPI 1548244825
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,314 of the $9,492 with a category attached, or 66.5%. It is spread thinly across 24 manufacturers, the largest accounting for just 18.6%. Reporting peaked in 2019 at $2,864 and has fallen 57.2% since, to $1,227 in 2025.
Across 354 payments — averaging $26.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- AstraZeneca$2K
- Shire North American Group Inc$1K
- GSK$1K
- Sanofi$933
- Regeneron Healthcare Solutions, Inc.$587
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$3,08332%
- Food & beverage$6,31467%
- Education$961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $1,766 |
| AstraZeneca | 69 | $1,678 |
| Shire North American Group Inc | 7 | $1,466 |
| GSK | 116 | $1,389 |
| Sanofi | 48 | $933 |
| Regeneron Healthcare Solutions, Inc. | 31 | $587 |
| Boehringer Ingelheim | 14 | $253 |
| Alk-abello, Inc | 4 | $250 |
| Genentech USA, Inc. | 10 | $205 |
| CSL Behring | 4 | $182 |
| Covis Pharma GmbH | 8 | $129 |
| Octapharma USA, Inc. | 4 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $96 |
| Hikma Pharmaceuticals USA | 5 | $96 |
| Pfizer | 6 | $82 |
| Kaleo, Inc. | 5 | $80 |
| Pharming Healthcare, Inc. | 2 | $40 |
| Amgen | 2 | $38 |
| Novartis | 2 | $33 |
| Lilly USA, LLC | 1 | $21 |
| Biocryst US Sales Co., LLC | 1 | $17 |
| Merck | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Optinose US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ArmonAir Digihaler$1,680
- AirDuo RespiClick$1,680
- ProAir Digihaler$1,680
- HYQVIA$1,403
- Odactra$167
- DUPIXENT$121
- NUCALA$109
- FASENRA$105
How this compares
$9,492 in reported general payments places this provider in the 85th percentile of 47 allergy providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 24 | $110,757 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $45,092 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $18,247 |
| Arnuity ElliptaFluticasone Furoate | 27 | $10,673 |
| Qvar RedihalerBeclomethasone Dipropionate | 20 | $7,153 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,405 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,217 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,290 |
| Montelukast Sodium | 53 | $674 |
| Ipratropium Bromide | 27 | $672 |
| Fluticasone Propionate | 26 | $468 |
| Azelastine Hcl | 31 | $283 |
| Prednisone | 16 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $96 | $110,75724 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,389 | $74,012117 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $1,766 | $7,15320 claims |
| AstraZenecaSymbicort | $1,678 | $3,40513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 allergy providers in Illinois.
Other allergy in Orland Park
- Sai NimmagaddaOrland Park$14K
- James HunterOrland Park$2K
- Michael FlaisOrland Park$1K
- James ThompsonOrland Park$744
- Saroj KhuranaOrland Park$131
- Timothy BrownOrland Park$114
- Ewa SchaferGlenview$165K
- Brian RotskoffChicago$82K
- Bruce BochnerChicago$43K
- Mark MillerHoffman Estates$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.